Which is better, ABUS or HALO?

On the Buffett-Fit framework, Halozyme Therapeutics, Inc. (HALO) currently grades higher than ABUS — 79/100 (B grade) vs 49/100 (D). That said, "better" depends on which framework you trust — ABUS wins on Joel Greenblatt; HALO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ABUS or HALO?

This page is an educational comparison, not investment advice. Both ABUS and HALO are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ABUS better than HALO for value investing?

On the Buffett-style value-investing framework, HALO currently grades higher — 79/100 vs 49/100, a 30-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ABUS and HALO on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ABUS currently scores 49/100 (D grade); HALO scores 79/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ABUS or HALO?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ABUS and HALO are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ABUS or HALO?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ABUS and HALO both Healthcare stocks?

Yes — both Arbutus Biopharma Corporation (ABUS) and Halozyme Therapeutics, Inc. (HALO) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ABUS vs HALO comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Arbutus Biopharma

ABUS$859.29MHealthcare Market cap, Sector

Halozyme Therapeutics

HALO$8.1BHealthcare Market cap, Sector

Overall winner

Halozyme Therapeutics

ABUS 1 HALO

Fit scores by strategy

ABUS1wins

6winsHALO

Warren Buffett

49D

B79

Benjamin Graham

43F

B83

Philip Fisher

55D

C65

Peter Lynch

48D

D53

Joel Greenblatt

100A

F40

Charlie Munger

64C

B80

Terry Smith

66C

B84

Side-by-side metrics

Metric	ABUS	HALO
Market cap	$859.29M	$8.1B Winner
P/E (TTM)	Winner: 5.1x	24.0x
EV/EBIT	Winner: -	10.2x
ROIC (TTM)

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ABUS leads on

EV/EBIT-vs 10.2x+134%
Debt / Equity0.0xvs 1.0x+100%
P/E (TTM)5.1xvs 24.0x+79%
Net margin83.95%vs 23.13%+72%

HALO leads on

More like ABUS

ABUS vs PME.AX ABUS vs CAMX.ST ABUS vs BSLN.SW ABUS vs 1681.HK

More like HALO

HALO vs PME.AX HALO vs CAMX.ST

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Industries

Rankings

Glossary

Tools & Methodology

Arbutus Biopharma

Halozyme Therapeutics

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like ABUS

More like HALO

Related on invest-like

Key terms in this analysis